Established in 2016, Salignostics has developed a novel technology which utilizes saliva for lateral flow immunoassay applications. Our vision is to transform the next generation of in-vitro diagnostics by developing easy, clean, safe, low-cost, accessible and reliable saliva-based products.
SaliCov is an innovative antigen saliva test that detects the presence of COVID-19 in both symptomatic and asymptomatic patients.
This unique tool does not require professional personnel or laboratory equipment, enabling fast and easy screening of large populations.
SaliCov can be performed anywhere by anyone. The broad applicability of this test will enable accurate and rapid diagnostics that will enable schools, workplaces, and cultural attractions to reopen their doors.
SaliCov has been selected by the NIH Rapid Acceleration of Diagnostics (RADx) initiative. This program focuses on mass production scale up of COVID-19 innovative diagnostic products.
This milestone driven program promotes US distribution of the awarded products funded by the US government.